P240045: Optimum Infinite (tisilfocon A) Orthokeratology Lenses II
FDA’s recorded scope: Approval for Optimum Infinite (tisilfocon A) Ortho-k Lenses, Optimum Infinite (tisilfocon A) Orthokeratology Lenses II.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Contamac, Ltd.. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Feb 10, 2026 to Feb 10, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NUU appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240045, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: Carlton House, Shire Hill, Saffron Walden, CB11 3AU. Recorded on P240045, decision dated Feb 10, 2026.
FDA’s recorded scope: Approval for Optimum Infinite (tisilfocon A) Ortho-k Lenses, Optimum Infinite (tisilfocon A) Orthokeratology Lenses II.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Contamac, Ltd. | PMA approval | Feb 10, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.